BRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis

Reuters

10 May

BRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis

May 10 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O:

MADRIGAL ANNOUNCES NEW CLINICAL DATA DEMONSTRATING REZDIFFRA™ (RESMETIROM) SIGNIFICANTLY IMPROVED MULTIPLE NONINVASIVE TESTS AND PORTAL HYPERTENSION RISK IN PATIENTS WITH COMPENSATED MASH CIRRHOSIS
MADRIGAL PHARMACEUTICALS INC - PATIENTS ACHIEVED 6.7 KPA REDUCTION IN LIVER STIFFNESS
MADRIGAL PHARMACEUTICALS INC - REZDIFFRA WELL-TOLERATED WITH LOW DISCONTINUATION RATE
MADRIGAL PHARMACEUTICALS: 65% OF PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AT BASELINE MOVED INTO LOWER RISK CATEGORIES BY YEAR TWO

Source text: ID:nGNX1DmCGG

Further company coverage: MDGL.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2534441420"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2534441420\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2534441420?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-10 19:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2534441420","market":"nz","top_or_hot":-1,"title":"BRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests &amp; Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis</title></head><body><p><span>May 10 (Reuters)</span><span> - </span>Madrigal Pharmaceuticals Inc <span>MDGL.O</span>:</p><ul><li><p>MADRIGAL ANNOUNCES NEW CLINICAL DATA DEMONSTRATING REZDIFFRA™ (RESMETIROM) SIGNIFICANTLY IMPROVED MULTIPLE NONINVASIVE TESTS AND PORTAL HYPERTENSION RISK IN PATIENTS WITH COMPENSATED MASH CIRRHOSIS</p></li><li><p>MADRIGAL PHARMACEUTICALS INC - PATIENTS ACHIEVED 6.7 KPA REDUCTION IN LIVER STIFFNESS</p></li><li><p>MADRIGAL PHARMACEUTICALS INC - REZDIFFRA WELL-TOLERATED WITH LOW DISCONTINUATION RATE</p></li><li><p>MADRIGAL PHARMACEUTICALS: 65% OF PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AT BASELINE MOVED INTO LOWER RISK CATEGORIES BY YEAR TWO</p></li></ul><p>Source text: <span>ID:nGNX1DmCGG</span></p><p>Further company coverage: <span>MDGL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-10 19:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests &amp; Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis</title></head><body><p><span>May 10 (Reuters)</span><span> - </span>Madrigal Pharmaceuticals Inc <span>MDGL.O</span>:</p><ul><li><p>MADRIGAL ANNOUNCES NEW CLINICAL DATA DEMONSTRATING REZDIFFRA™ (RESMETIROM) SIGNIFICANTLY IMPROVED MULTIPLE NONINVASIVE TESTS AND PORTAL HYPERTENSION RISK IN PATIENTS WITH COMPENSATED MASH CIRRHOSIS</p></li><li><p>MADRIGAL PHARMACEUTICALS INC - PATIENTS ACHIEVED 6.7 KPA REDUCTION IN LIVER STIFFNESS</p></li><li><p>MADRIGAL PHARMACEUTICALS INC - REZDIFFRA WELL-TOLERATED WITH LOW DISCONTINUATION RATE</p></li><li><p>MADRIGAL PHARMACEUTICALS: 65% OF PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AT BASELINE MOVED INTO LOWER RISK CATEGORIES BY YEAR TWO</p></li></ul><p>Source text: <span>ID:nGNX1DmCGG</span></p><p>Further company coverage: <span>MDGL.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250510:nTUA4V67G6:1","article_id":"2534441420","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2534441420","pubTimestamp":1746875976,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash CirrhosisMay 10 (Reuters) -","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"BRIEF-Madrigal表示，新的临床数据表明Rezdiffra显着改善了代偿性Mash肝硬化患者的多项无创检查和门静脉高压症风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":0.9},"content_text":"BRIEF-Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash CirrhosisMay 10 (Reuters) - Madrigal Pharmaceuticals Inc MDGL.O:MADRIGAL ANNOUNCES NEW CLINICAL DATA DEMONSTRATING REZDIFFRA™ (RESMETIROM) SIGNIFICANTLY IMPROVED MULTIPLE NONINVASIVE TESTS AND PORTAL HYPERTENSION RISK IN PATIENTS WITH COMPENSATED MASH CIRRHOSISMADRIGAL PHARMACEUTICALS INC - PATIENTS ACHIEVED 6.7 KPA REDUCTION IN LIVER STIFFNESSMADRIGAL PHARMACEUTICALS INC - REZDIFFRA WELL-TOLERATED WITH LOW DISCONTINUATION RATEMADRIGAL PHARMACEUTICALS: 65% OF PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AT BASELINE MOVED INTO LOWER RISK CATEGORIES BY YEAR TWOSource text: ID:nGNX1DmCGGFurther company coverage: MDGL.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}